Abstract
Go.10213, a new nitroimidazole, was studied in 12 male volunteers for tolerability and in 20 patients with intestinal amoebiasis for antiamoebic activity. Go.10213 was well-tolerated by volunteers up to a dose of 400 mg X 3. Patients also tolerated well the dose of 100-150 mg X 3 for 7 days. In two patients, there were mild and transient side-effects like headache, dizziness, fatigue, etc. No neurological side-effects were observed. There were no significant changes in blood pressure, pulse rate and ECG. The organ function tests did not show any adverse effects of Go.10213 on bone-marrow, kidney, liver, etc. Go.10213, at a dose of 150 mg X 3, showed potent antiamoebic activity in 10 patients with intestinal amoebiasis, as judged by the clinical relief, the eradication of the trophozoites and cysts of Entamoeba histolytica from stools and the healing of colonic ulcers. Go.10213, a novel nitroimidazole, may prove to be the most potent and safe agent against the protozoal infections, e.g. amoebiasis, giardiasis and trichomoniasis.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Doshi J. C., Doshi M. J., Vaidya A. B., Mehta J. M., Sheth U. K. Niridazole in amebic dysentery and hepatic amebiasis. Am J Trop Med Hyg. 1968 Sep;17(5):702–708. doi: 10.4269/ajtmh.1968.17.702. [DOI] [PubMed] [Google Scholar]
- Koch-Weser J., Goldman P. Drug therapy: metronidazole. N Engl J Med. 1980 Nov 20;303(21):1212–1218. doi: 10.1056/NEJM198011203032106. [DOI] [PubMed] [Google Scholar]
- Ray D. K., Chatterjee D. K., Tendulkar J. S. Comparative efficacy of Go 10213 and some nitroimidazoles against Trichomonas vaginalis and T. Foetus in mice infected subcutaneously. Ann Trop Med Parasitol. 1982 Apr;76(2):175–178. doi: 10.1080/00034983.1982.11687524. [DOI] [PubMed] [Google Scholar]